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OBJECTIVE—The present study was conducted to conﬁrm
possible associations between candidate genes from genome-
wide association studies and type 2 diabetes in Japanese diabetic
patients and a community-based general population. A total of 11
previously reported single-nucleotide polymorphisms (SNPs)
from the TCF7L2, CDKAL1, HHEX, IGF2BP2, CDKN2A/B,
SLC30A8, and KCNJ11 genes were analyzed.
RESEARCH DESIGN AND METHODS—Candidate SNPs were
genotyped in 506 type 2 diabetic patients and 402 control
subjects and meta-analyzed with six previous association studies
in Japanese patients. Associations with fasting plasma insulin
levels were investigated in a general population sample (n 
1,963, 61  13 years).
RESULTS—In our case-control subjects, susceptibility to type 2
diabetes was replicated in TCF7L2 (rs12255372), CDKAL1
(rs7756992, rs7754840), HHEX (rs7923837), IGF2BP2 (rs4402960
and rs1470579), CDKN2A/B (rs10811661), and SLC30A8
(rs13266634). In addition to these polymorphisms, meta-analysis
conﬁrmed the association of type 2 diabetes susceptibility with
KCNJ11 rs5219, TCF7L2 rs7903146, and HHEX rs1111875. The
TCF7L2 rs12255372 polymorphism showed the highest odds
ratio (OR) for type 2 diabetes (OR 1.714 [1.298–2.263]). Odds
ratio of other polymorphisms ranged from 1.13 to 1.41. The risk
allele of CDKAL1 rs7756992 was signiﬁcantly associated with
lower insulin levels in type 2 diabetic patients after adjustment
for other confounding factors.
CONCLUSIONS—Type 2 diabetes susceptibility of seven can-
didate genes was conﬁrmed in Japanese. Conservation of sus-
ceptible loci for type 2 diabetes was independent of ethnic
background. Diabetes 58:493–498, 2009
A
great number of studies in various populations
have suggested an association between several
single-nucleotide polymorphisms (SNPs) and
type 2 diabetes. For example, transcription
factor 7-like 2 (TCF7L2) is a highly reliable predisposing
gene for type 2 diabetes (1–3). In addition, recent genome-
wide association studies (GWASs) have provided new
susceptible loci for type 2 diabetes (4–10). A GWAS in
French subjects, for example, identiﬁed rs13266634, a
nonsynonymous SNP (R325W) on the solute carrier family
30 member 8 (SLC30A8) gene, as a polymorphism in-
volved in type 2 diabetes susceptibility (4). The study also
reported an association between type 2 diabetes and
rs1111875, as well as rs7923837, located in the hematopoi-
etically expressed homeobox gene (HHEX). These associ-
ations were replicated in three independent GWASs in
various populations (5–7).
Additional susceptible SNPs were independently identi-
ﬁed in the insulin-like growth factor 2 mRNA-binding
protein 2 gene (IGF2BP2, rs4402960, and rs1470569) (5,6).
Involvement of SNPs rs10811661, located upstream of
cyclin-dependent kinase inhibitor genes CDKN2A and
CDKN2B, and “rs7754840/rs7756992,” located in the CDK5
regulatory subunit-associated protein 1-like 1 gene
(CDKAL1), has also been suggested (5,6,8,9). A recent
population-based study in Danish subjects replicated the
susceptible association of HHEX rs111875, CDKN2A/B
rs10811661, and IGF2BP2 rs4402960 with type 2 diabetes
(10).
Findings from previous GWASs, however, cannot be
extrapolated to other populations with different lifestyles
and environmental backgrounds. In particular, the genetic
background for type 2 diabetes development in East
Asians, who show lower basal insulin secretion and a
marked decrease in insulin release in response to devel-
opment of glucose tolerance (11), appears to be different
from that in Caucasians or individuals of European origin.
Further, SNP frequency differences are suggested to be an
additional factor inﬂuencing type 2 diabetes susceptibility.
Here, based on a recent GWAS (4–10), we conducted a
replication study of candidate SNPs associated with type 2
diabetes in Japanese diabetic subjects, as well as in a
general Japanese population sample.
RESEARCH DESIGN AND METHODS
Case and control subjects. Basic clinical characteristics of subjects are
summarized in Supplemental Table 1 (located in an online appendix at
http://dx.doi.org/10.2337/db07-1785). All type 2 diabetic subjects (n  506)
were inpatients or outpatients evaluated by diabetes specialists at Ehime
University Hospital and Ehime Prefectural Hospital in Japan. Diabetes was
diagnosed based on the 1998 American Diabetes Association criteria (12).
Nondiabetic control subjects (n  402) were chosen based on the absence of
a history of diabetes in the subject and among ﬁrst-degree relatives, as well as
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DIABETES, VOL. 58, FEBRUARY 2009 493either normal glucose tolerance, conﬁrmed by a 75-g oral glucose tolerance
test, or A1C levels 5.6 with fasting plasma glucose levels 110 mg/dl. All
case and control subjects were native Japanese. Selection criteria details have
been described in a previous study (13). A total of 139 type 2 diabetic patients
and 136 control subjects were overlapped with the previous meta-analysis for
TCF7L2 polymorphisms (14).
General population. The general population subjects were selected from
residents of a community of 11,000 inhabitants in Ehime Prefecture, a largely
rural area located in western Japan (15). Subjects were recruited through a
community-based annual medical checkup process for self-employees, includ-
ing farmers and foresters, employees of small companies, and elderly without
ﬁxed employment. The sample population consisted of 1,963 middle-aged to
elderly residents (Supplemental Table 2). Overnight fasting plasma samples
for the measurement of plasma insulin concentrations were available for all
sample subjects. Baseline clinical characteristics were obtained from personal
health records evaluated during the medical checkup. All study procedures
were approved by the ethics committee of the Ehime University Graduate
School of Medicine, and informed consent was obtained from each partici-
pating subject.
Genotyping. Genomic DNA was extracted from peripheral blood (QIAamp
DNA blood kit; QIAGEN, Hilden, Germany). All SNPs were analyzed by
TaqMan probe assay (Applied Biosystems, Foster City, CA) using commer-
cially available primers and probes purchased from the Assay-on-Demand
system (Supplemental Table 3).
Statistical analysis. Data are expressed as means  SD. Linkage disequilib-
rium was assessed using the Haploview software (Broad Institute, Cambridge,
MA) (16). Frequency differences in each genotype were assessed by the 
2
test. The pooled odds ratios for allele frequency with those of six other
association studies in Japanese (17–22) were estimated using the ﬁxed-effects
model (Mantel-Haenszel method). Differences in plasma insulin levels among
genotypes (ANOVA and multiple regression analysis [additive model] adjusted
for age, sex, and BMI) were assessed using a commercially available statistical
software package (SPSS Version 14.0; SPSS, Chicago, IL). Current treatment
of hyperglycemia was further adjusted in type 2 diabetic patients when
appropriate. Null hypotheses were rejected at a level of signiﬁcance of P 
0.05.
RESULTS
Table 1 summarizes the association between 11 candidate
SNPs and type 2 diabetes in case-control subjects. The T
allele of TCF7L2 (rs12255372) was signiﬁcantly associated
with type 2 diabetes. A tendency to association was also
observed with SNP rs7903146, which was in linkage dis-
equilibrium with rs12255372 (D0.854, r
2  0.421).
However, the risk allele frequency of these SNPs was
considerably low, which is in agreement with previous
reports in Japanese subjects (17,18). The post hoc calcu-
lated statistical power of these SNPs (allele frequency)
was 36.1% and 25.4% for rs12255372 and rs7903146, respec-
tively, with a 5% type 1 error rate.
In addition to TCF7L2 polymorphisms, a signiﬁcant
association was observed between type 2 diabetes and
polymorphisms in CDKAL1 (rs7756992 [power: 51.0%],
rs7754840 [52.9%]; D0.920; r
2  0.648), HHEX (rs7923837
[30.4%]), IGF2BP2 (rs4402960 [31.3%], rs1470579 [51.1%];
D0.997; r
2  0.918), CDKN2A/B (rs10811661
[32.6%]), and SLC30A8 (rs13266634 [10.7%]), but not
HHEX (rs1111875 [8.5%]). Further, a marginally signiﬁ-
cant association was observed between type 2 diabetes
and the KCNJ11 polymorphism (rs5219 [21.8%])). Com-
pared with control subjects of European descent,
risk allele frequencies in Japanese control subjects were
higher in the CDKAL1 gene (rs7756992 G allele, 0.470 vs.
0.258) and lower in the HHEX (rs1111875 C allele, 0.288 vs.
0.598; rs7923837 G allele, 0.177 vs. 0.597), CDKN2A/B
(rs10811661 T allele, 0.555 vs. 0.850), SLC30A8 (rs13266634
C allele, 0.568 vs. 0.699), and KCNJ11 (rs5219 T allele,
0.372 vs. 0.464) genes (4,6,8). In contrast, no signiﬁcant
frequency differences were observed in the CDKAL1
rs7754840 (C allele, 0.399 vs. 0.360) and IGF2BP2
rs4402960 (T allele, 0.287 vs. 0.304) polymorphisms.
However, except for the CDKAL polymorphisms, statis-
tical signiﬁcance was not reached in the observed associ-
ations using Bonferroni’s correction, possibly due to
limited statistical power. To further clarify type 2 diabetes
susceptibility, seven association studies in Japanese sub-
jects (17–22), including our present data, were meta-
analyzed (Fig. 1). Type 2 diabetes susceptibility was
conﬁrmed in all analyzed polymorphisms, both before and
after Bonferroni’s adjustment. Further, two SNPs
(rs1111875 in HHEX and rs5219 in KCNJ11), which were
not replicated in our data, were conﬁrmed as susceptible
polymorphisms for type 2 diabetes.
To further clarify the pathophysiological signiﬁcance of
the susceptibility of these seven genes for type 2 diabetes,
associations with plasma insulin levels were evaluated in a
community-derived population sample (Table 2). Although
differences in plasma insulin levels among the CDKAL1
rs7756992 genotype did not reach statistical signiﬁcance,
probably due to the limited statistical power (post hoc
calculated statistical power: 28.3% for type 2 diabetic
patients, 31.8% for control subjects), multiple regression
analysis involving the genotype as an additive model
showed signiﬁcantly lower insulin levels in type 2 diabetic
subjects with risk genotypes after adjusting for age, sex,
and BMI. The association of CDKAL1 rs7756992 remained
signiﬁcant after further adjustment for the current treat-
ment of hyperglycemia (n  67, P  0.021). The risk allele
of CDKAL1 rs7754840 also tended to be associated with
lower insulin levels. However, no signiﬁcant associations
were observed in other SNPs.
DISCUSSION
In the present study, we replicated the associations of
several candidate genes derived from a recent GWAS
(4–10). However, several conﬂicting results were observed
with other replication studies in Japanese diabetic pa-
tients. Horikoshi et al. (21) and Furukawa et al. (20)
observed a markedly strong association between type 2
diabetes and variants of HHEX rs1111875, whereas no
association was observed in our study. However, results of
our meta-analysis (Fig. 1) clearly indicate the type 2
diabetes susceptibility of all candidate genes, including
HHEX rs1111875. Conservation of susceptible loci for type
2 diabetes was independent of ethnic background.
However, the attributable risk of these SNPs susceptible
for type 2 diabetes was different from that of European
ancestries. For example, the pooled odds ratios of the
TCF7L2 gene polymorphisms were slightly higher than
those in European ancestries (6,23), whereas the risk
allele frequencies were considerably lower. Alternatively,
for HHEX gene polymorphisms, odds ratios were slightly
higher in Japanese (7). Very recently, genome-wide screen-
ing in a Japanese population identiﬁed the KCNQ1 gene
polymorphism as a new susceptible loci for type 2 diabetes
(24). These authors reported that the risk alleles of
rs2237892 and other SNPs in linkage disequilibrium with
rs2237892 were associated with an increased risk of type 2
diabetes. However, apparent associations of the KCNQ1
SNPs were not observed in previous GWAS in populations
of European descent (4–10). This discrepancy may be due
mainly to the differences in allele frequencies of the
susceptible SNPs.
It has been suggested that several candidate SNPs
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DIABETES, VOL. 58, FEBRUARY 2009 495identiﬁed from genome-wide screening contribute to dia-
betes susceptibility primarily through effects on insulin
secretion. In our quantitative trait analysis in a general
Japanese population, we observed lower basal plasma
insulin levels in type 2 diabetic patients carrying the risk
genotype of CDKAL1 rs7756992 SNP. Although the func-
tion of the CDKAL1 gene product is unknown, one study
suggested that CDKAL1 has a role in the inhibition of
cyclin-dependent kinase 5 (CDK5) activity in pancreatic
-cells (8), which prevents a decrease in insulin gene
expression resulting from glucotoxicity. That study also
observed reduced insulin secretion in response to glucose
loading in homozygous carriers of the CDKAL1 rs7756992
polymorphism risk allele (8). Pascoe et al. (25) also
reported lower insulin secretion after glucose loading in
risk allele carriers of another SNP of the CDKAL1 gene.
Our study is the ﬁrst to show a possible association
between this SNP and basal insulin levels in type 2 diabetic
patients. This observation provides supporting evidence
for the pathophysiological role of the CDKAL1 gene
products in the progression of type 2 diabetes, as well as
the disease susceptibility of this genetic variant.
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1.144 (1.078-1.213), p=7.8*10-6
1.126 (1.039-1.219), p=0.004
FIG. 1. Meta-analysis of type 2 diabetes genetic association studies in Japanese. Estimation of odds ratios and 95% CIs in each study are displayed
as a closed square and horizontal line, respectively. Square size represents the study weighting. Combined odds ratio is represented as the
diamond. Study A, present study; Study B, Hayashi et al. (18); Study C, Horikoshi et al. (17); Study D, Horikawa et al. (19); Study E, Furukawa
et al. (20); Study F, Horikoshi et al. (21); Study G, Omori et al. (22).
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First, differences in linkage disequilibrium between
Japanese and European subjects means that tracking of
the causal variants may not be possible in SNPs based
on the association study in European ancestries. Al-
though our meta-analysis showed an association be-
tween type 2 diabetes susceptibility and the analyzed
candidate SNPs, causal variants may also be strongly
represented by other SNPs in Japanese subjects. Studies
with multiple tag-SNPs at loci chosen based on the
linkage disequilibrium pattern in Japanese may provide
further clariﬁcation of this issue. Second, we did not
investigate the class of antihyperglycemic drugs, includ-
ing insulin treatment, in the general population sample.
Although each drug may have affected fasting plasma
insulin differently, association of the CDKAL1 genotype
with plasma insulin levels was statistically signiﬁcant
after further adjustment for current treatment for
hyperglycemia.
In the present study, we replicated several genetic
variants as risk markers for type 2 diabetes susceptibility
in Japanese by performing a case-control analysis and
meta-analysis. These ﬁndings may be useful in advanced
clinical practice and public health genomics.
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